Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 7, 2017, Pages 1660-1665

  Wu, Wenbo ^a,b   Lu, Zhiwei ^b   Li, Fei ^b   Wang, Wenjie ^b   Qian, Nannan ^b   Duan, Jinzhi ^b   Zhang, Yu ^b   Wang, Fengchao ^b   Chen, Ting ^b  

^a PEKING UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES   (China)

Author keywords

Cas9 sgRNA ribonucleoproteins; Electroporation; In vivo gene editing; RDEB; Skin stem cell

Indexed keywords

CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN 9; COLLAGEN TYPE 7; GENOMIC DNA; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG; COL7A1 PROTEIN, MOUSE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; ELECTROPORATION; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EXON SKIPPING; FLUORESCENCE ACTIVATED CELL SORTING; GENE EDITING; GENETIC DISORDER; GENOTYPE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SKIN CELL; STEM CELL; ANIMAL; CRISPR CAS SYSTEM; DISEASE MODEL; GENE THERAPY; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; RECESSIVE GENE; REPRODUCIBILITY; SKIN; TRANSGENIC MOUSE;

ANIMALS; COLLAGEN TYPE VII; CRISPR-CAS SYSTEMS; DISEASE MODELS, ANIMAL; EPIDERMOLYSIS BULLOSA DYSTROPHICA; GENE EDITING; GENES, RECESSIVE; GENETIC THERAPY; HUMANS; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; REPRODUCIBILITY OF RESULTS; RIBONUCLEOPROTEINS; SKIN; STEM CELLS;

EID: 85013028996     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1614775114     Document Type: Article

References (33)

1. Cong L, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819-823.
2. Doudna JA, Charpentier E (2014) Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096.
3. Mali P, et al. (2013) RNA-guided human genome engineering via Cas9. Science 339(6121):823-826.
4. Maddalo D, et al. (2014) In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516(7531):423-427.
5. Yin H, et al. (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32(6):551-553.
6. Swiech L, et al. (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33(1):102-106.
7. Chiou SH, et al. (2015) Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes Dev 29(14):1576-1585.
8. Tabebordbar M, et al. (2016) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351(6271):407-411.
9. Long C, et al. (2016) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351(6271):400-403.
10. Nelson CE, et al. (2016) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351(6271):403-407.
11. Lunstrum GP, Sakai LY, Keene DR, Morris NP, Burgeson RE (1986) Large complex globular domains of type VII procollagen contribute to the structure of anchoring fibrils. J Biol Chem 261(19):9042-9048.
12. Sakai LY, Keene DR, Morris NP, Burgeson RE (1986) Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol 103(4):1577-1586.
13. Uitto J, Pulkkinen L (1996) Molecular complexity of the cutaneous basement membrane zone. Mol Biol Rep 23(1):35-46.
14. Burgeson RE (1993) Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Dermatol 101(3):252-255.
15. Bruckner-Tuderman L (2010) Dystrophic epidermolysis bullosa: Pathogenesis and clinical features. Dermatol Clin 28(1):107-114.
16. Remington J, et al. (2009) Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 17(1):26-33.
17. Woodley DT, et al. (2004) Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 10(7):693-695.
18. Ortiz-Urda S, et al. (2003) Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 111(2):251-255.
19. Woodley DT, et al. (2003) Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 121(5):1021-1028.
20. Wong T, et al. (2008) Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 128(9):2179-2189.
21. Gache Y, et al. (2004) Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther 15(10):921-933.
22. Chen M, et al. (2002) Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 32(4):670-675.
23. Ortiz-Urda S, et al. (2002) Stable nonviral genetic correction of inherited human skin disease. Nat Med 8(10):1166-1170.
24. Sebastiano V, et al. (2014) Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Sci Transl Med 6(264):264ra163.
25. Wenzel D, et al. (2014) Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa. Sci Transl Med 6(264):264ra165.
26. Umegaki-Arao N, et al. (2014) Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa. Sci Transl Med 6(264):264ra164.
27. Bilousova G, Roop DR (2014) Induced pluripotent stem cells in dermatology: Potentials, advances, and limitations. Cold Spring Harb Perspect Med 4(11):a015164.
28. Ferrari S, Pellegrini G, Matsui T, Mavilio F, De Luca M (2006) Towards a gene therapy clinical trial for epidermolysis bullosa. Rev Recent Clin Trials 1(2):155-162.
29. Kiuru M, Itoh M, Cairo MS, Christiano AM (2010) Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. Dermatol Clin 28(2):371-382, xii-xiii.
30. Wagner JE, et al. (2010) Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 363(7):629-639.
31. Naldaiz-Gastesi N, et al. (2016) Identification and characterization of the dermal panniculus carnosus muscle stem cells. Stem Cell Reports 7(3):411-424.
32. Liang X, et al. (2015) Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol 208:44-53.
33. Zuris JA, et al. (2015) Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 33(1):73-80.